Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biological activity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    555 result(s) found for: Biological activity. Displaying page 7 of 28.
    EudraCT Number: 2010-023677-19 Sponsor Protocol Number: VITAD-2010 Start Date*: 2011-03-23
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: Bio-molecular effects of interferon-beta and d-vitamin association
    Medical condition: PATIENT WITH RRMS AND SPMS
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001823-15 Sponsor Protocol Number: 20CH089 Start Date*: 2020-04-28
    Sponsor Name:CHU de Saint Etienne
    Full Title: Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study
    Medical condition: covid-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10070267 SARS virus test positive LLT
    21.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003680-38 Sponsor Protocol Number: HDVitC Start Date*: 2015-06-12
    Sponsor Name:VU university medical center
    Full Title: Pharmacokinetics of two different high dose regimes of intravenous vitamin C in critically ill patients
    Medical condition: Critically ill patients with trauma or sepsis exhibit a high degree of vitamin C deficiency at ICU admission and vitamin C plasma concentrations decrease even more during the first three days of ad...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001170-15 Sponsor Protocol Number: CECUM Start Date*: 2017-10-19
    Sponsor Name:GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis ulcerosa)
    Full Title: Efficacy of high-dose corticosteroid pulses added to conventional oral corticosteroid course in comparison with monotherapy oral corticosteroid course for moderate flares of ulcerative colitis: a...
    Medical condition: Moderate flares of Ulcerative Colitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011251-48 Sponsor Protocol Number: CNTO888PCR2001 Start Date*: 2009-08-28
    Sponsor Name:Janssen Biologics B.V.
    Full Title: An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects with Metastatic Castrate-Resistant Prostate Cancer
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000563-41 Sponsor Protocol Number: IMIMFTCL/GH/4 Start Date*: 2014-08-08
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
    Full Title: Recombinant hGH Biomarkers Discovery
    Medical condition: Healthy volunteers. There is not intended indication.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018900-10 Sponsor Protocol Number: FLIP110 Start Date*: 2010-05-11
    Sponsor Name:Laboratoires Mayoly Spindler
    Full Title: Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis
    Medical condition: Exocrine pancreatic insufficiency resulting from chronic pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10033628 Pancreatic insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001727-12 Sponsor Protocol Number: TPV11 Start Date*: 2019-10-24
    Sponsor Name:Topas Therapeutics GmbH
    Full Title: A multi-centre, open-label, phase 1 study, Part A single ascending dose and Part B multiple dose, to evaluate the safety, tolerability and pharmacokinetics, and to explore early signs of effectiven...
    Medical condition: Pemphigus vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003138-17 Sponsor Protocol Number: P1200_51 Start Date*: 2020-01-17
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: A 24 weeks proof of concept study to evaluate the clinical, MRI and synovial tissue benefit of Sarilumab in active RA patients despite TNF agents
    Medical condition: Medical condition – Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000666-10 Sponsor Protocol Number: m16-063 Start Date*: 2018-12-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subje...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001753-17 Sponsor Protocol Number: ATYR1940-C-002 Start Date*: 2014-09-19
    Sponsor Name:aTyr Pharma, Inc.
    Full Title: A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Define...
    Medical condition: Facioscapulohumeral muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10064087 Facioscapulohumeral muscular dystrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001350-21 Sponsor Protocol Number: APL2-PNH-209 Start Date*: 2020-12-08
    Sponsor Name:Apellis Pharmaceuticals, Inc.
    Full Title: An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10055629 Paroxysmal nocturnal hemoglobinuria LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002026-20 Sponsor Protocol Number: CT7001-001 Start Date*: 2017-10-31
    Sponsor Name:Carrick Therapeutics
    Full Title: A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malign...
    Medical condition: Module 1A: All solid malignancies Module 1B: Solid malignancies, potentially including TNBC, SCLC, CRPC, ovarian cancer patients, and other appropriate cancer indications. Module 1B-1 (TNBC):...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-006198-25 Sponsor Protocol Number: HE7/12 Start Date*: 2012-10-24
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: A Phase II, single-arm clinical trial of administration of cisplatin and 5-fluorouracil with afatinib as first-line therapy in patients with inoperable gastric or gastroesophageal junction cancer
    Medical condition: Inoperable gastric and gastroesophageal junction cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017760 Gastric cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001912-36 Sponsor Protocol Number: ATYR1940-C-005 Start Date*: 2015-08-04
    Sponsor Name:aTyr Pharma, Inc.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients with Facioscapulohumeral Muscular Dystrophy (F...
    Medical condition: Facioscapulohumeral muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10064087 Facioscapulohumeral muscular dystrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004494-13 Sponsor Protocol Number: INT-TET1-7371 Start Date*: 2018-04-09
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: IMPROVING TREATMENT STRATEGIES IN THYMIC EPITHELIAL TUMORS: A TYME COLLABORATIVE EFFORT
    Medical condition: Patients diagnosed with thymic carcinoma / thymoma B3 with areas of carcinoma with metastatic or relapsed non-pre-treated disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056296 Neoplasm of thymus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002514-40 Sponsor Protocol Number: CISTA-TB Start Date*: 2019-10-31
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis d...
    Medical condition: Pulmonary Mycobacterium tuberculosis infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10037440 Pulmonary tuberculosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002008-25 Sponsor Protocol Number: 4053-101 Start Date*: 2014-09-10
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) o...
    Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-001526-27 Sponsor Protocol Number: STH14707 Start Date*: 2007-06-19
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: ANZAC: A Randomised Phase II Feasibility Study Investigating The Biological Effects of the Addition of Zoledronic Acid To Neoadjuvant Comnination Chemotherapy On Invasive Breast Cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-005568-14 Sponsor Protocol Number: V72_60 Start Date*: 2015-06-08
    Sponsor Name:Novartis Pharma Services A.G.
    Full Title: A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Rout...
    Medical condition: Prophylaxis of meningococcal meningitiditis caused by Neisseria meningitidis bacterium, serogroup B
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 03:46:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA